HAE vs SYRE
Haemonetics vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | HAE | SYRE |
|---|
| AI Score |
49
|
67
|
| Price |
$108.42
|
$106.63
|
| P/E Ratio |
52.82×
|
-54.61×
|
| ROE |
12.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
57.4%
|
0.0%
|
| Debt / Equity |
1.40×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.2
|
57.1
|
| Beta |
0.518
|
3.026
|
| Expected Upside |
+30.2%
|
—
|
AI Committee View
Current Innellis committee reasoning for HAE versus SYRE.
SYRE leads by 18 points.
SYRE scores 67/100 (Buy) versus HAE at 49/100 (Watch).
HAE Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.54) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
- EPS declining -37.4% YoY despite any revenue growth — Growth
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical